Seltorexant

Seltorexant
Clinical data
Other namesMIN-202; JNJ-42847922; JNJ-922
Routes of
administration		By mouth
Drug classOrexin antagonist
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Elimination half-life2–3 hours[1]
Identifiers
IUPAC name
  • [5-(4,6-Dimethylpyrimidin-2-yl)-hexahydropyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
FormulaC21H22FN7O
Molar mass407.453 g·mol−1
3D model (JSmol)
SMILES
  • c4c(C)nc(nc4C)N5CC2CN(CC2C5)C(=O)c1c(cccc1F)-n3nccn3
InChI
  • InChI=1S/C21H22FN7O/c1-13-8-14(2)26-21(25-13)28-11-15-9-27(10-16(15)12-28)20(30)19-17(22)4-3-5-18(19)29-23-6-7-24-29/h3-8,15-16H,9-12H2,1-2H3/t15-,16+
  • Key:SQOCEMCKYDVLMM-IYBDPMFKSA-N

Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals for the treatment of insomnia and major depressive disorder (MDD).[2][3][4] As of December 2015, it is in phase II clinical trials for both insomnia and major depressive disorder.[3][5][6]

See also

References

  1. ↑ Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
  2. ↑ Christopher JA (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–38. doi:10.4155/ppa.14.46. PMID 25489915.
  3. 1 2 Zisapel N (March 2015). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs. 24 (3): 401–11. doi:10.1517/13543784.2015.987340. PMID 25423562. S2CID 8202006.
  4. ↑ Boss C, Roch C (August 2015). "Recent trends in orexin research--2010 to 2015". Bioorganic & Medicinal Chemistry Letters. 25 (15): 2875–87. doi:10.1016/j.bmcl.2015.05.012. PMID 26045032.
  5. ↑ "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
  6. ↑ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.